June 14, 2005
Biosynexus Incorporated Acquired by QVT Fund LP;
Irwin Scher Named CEO of Biosynexus Incorporated

October 30, 2003
Biosynexus' New Anti-microbial Agent Destroys MRSA Biofilm
Only Compound Shown to be Capable of Eliminating Biofilm and Killing S. aureus
 
October 14, 2003
Biosynexus Announces Successful Completion of Phase I/II Trial for Topical Anti-Staph Cream for Eradication of S. aureus Nasal Colonization
BSYX-L210 Meets Endpoints of Safety and Microbiological Activity
 
October 2, 2002
GlaxoSmithKline Biologicals and Biosynexus Announce
Partnership to Prevent Multi-resistant Bacteria Infection
 
May 14, 2002
Biosynexus Presents Results of
First Clinical Study of an Anti-staphylococcal Monoclonal Antibody